TerrAscend Promotes Ziad Ghanem To CEO

TerrAscend Corp. (OTCQX: TRSSF) (CSE:TER) announced that Ziad Ghanem has been promoted to the role of CEO in addition to his existing role as president of the company.

TerrAscend Corp. (OTCQX:TRSSF) (CSE:TER) announced that Ziad Ghanem has been promoted to the role of CEO in addition to his existing role as president of the company. Ghanem was most recently TerrAscend’s president and COO and was elected to the new role of CEO unanimously by TerrAscend’s board of directors.

Ghanem has served as president and COO at TerrAscend since January 2022. Throughout his 20-year career, Ghanem held several senior leadership positions across the pharmaceutical, healthcare services, cannabis and retail industries, including serving as president of Parallel, a vertically integrated, multi-state cannabis operator.

“Ziad is a phenomenal leader who has been instrumental in driving improvements across the organization. Over Ziad’s first 15 months with TerrAscend he has become a trusted friend, and my respect for his leadership, judgment and grit has grown immensely,” stated Jason Wild, executive chairman of TerrAscend. “He has done an outstanding job as president and COO, and I can’t imagine a more qualified person to assume the CEO role. I am grateful to have found someone who shares my passion for TerrAscend’s long term success. I look forward to continuing our strong working relationship in the future.”

Ghanem stated: “We are building something special at TerrAscend while keeping our team members and customers at the center of each decision we make. Over the last 15 months, I have witnessed a team with a level of commitment, passion and determination that is beyond impressive. I am deeply grateful to the board for their trust in me, and I am particularly thankful to Jason Wild for being my biggest supporter and mentor.”

Benzinga’s Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo by Esteban López on Unsplash

Total
0
Shares
Related Posts
Read More

FDA Experts Weigh In On Incannex’s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.

IXHL